Intention-to-Treat (ITT) is a principle used in the design and analysis of randomized controlled trials. It refers to the practice of analyzing all participants in the groups to which they were originally randomly assigned, regardless of whether they actually received the intended treatment or completed the study.
The ITT approach helps maintain the balance of baseline characteristics between treatment groups achieved through randomization. It also provides a more conservative estimate of treatment effect by including all randomized participants, which better reflects real-world scenarios where patients may not always adhere to prescribed treatments.
Intention-to-Treat (ITT) is crucial in clinical research as it helps maintain the integrity of randomization and minimizes bias in treatment effect estimates. By analyzing all randomized participants, regardless of protocol deviations, ITT provides a more realistic assessment of treatment effectiveness in real-world settings where perfect adherence is rare.
ITT analysis is also important for regulatory purposes and is often required by agencies like the FDA for pivotal clinical trials. It helps prevent overestimation of treatment effects that can occur when only compliant participants are analyzed, thus providing a more conservative and reliable basis for healthcare decision-making.
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
Copyright @ 2026 Axcellant